InVivo Therapeutics Statistics
Share Statistics
InVivo Therapeutics has 3.11M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 3.11M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 156,772 |
| FTD / Avg. Volume | 4.16% |
Short Selling Information
The latest short interest is 17.63K, so 0.57% of the outstanding
shares have been sold short.
| Short Interest | 17.63K |
| Short % of Shares Out | 0.57% |
| Short % of Float | 0.64% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.35 and the forward
PE ratio is null.
InVivo Therapeutics's PEG ratio is
0.03.
| PE Ratio | -0.35 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.23 |
| P/FCF Ratio | -0.34 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
InVivo Therapeutics has an Enterprise Value (EV) of -11.79M.
| EV / Sales | 0 |
| EV / EBITDA | 1.16 |
| EV / EBIT | 1.12 |
| EV / FCF | 1.11 |
Financial Position
The company has a current ratio of 7.13,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.13 |
| Quick Ratio | 7.13 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.09 |
| Debt / FCF | -0.09 |
| Interest Coverage | -70.53 |
Financial Efficiency
Return on Equity is -64.64% and Return on Invested Capital is -61.9%.
| Return on Equity | -64.64% |
| Return on Assets | -54.08% |
| Return on Invested Capital | -61.9% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,696,500 |
| Employee Count | 6 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -311K |
| Effective Tax Rate | 2.96% |
Stock Price Statistics
The stock price has increased by 23.08% in the
last 52 weeks. The beta is 0.66, so InVivo Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.66 |
| 52-Week Price Change | 23.08% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 38.1 |
| Average Volume (20 Days) | 3,769,288 |
Income Statement
| Revenue | n/a |
| Gross Profit | -445K |
| Operating Income | -10.65M |
| Net Income | -10.18M |
| EBITDA | -10.21M |
| EBIT | -10.34M |
| Earnings Per Share (EPS) | -6.62 |
Full Income StatementBalance Sheet
The company has 16.35M in cash and 949K in
debt, giving a net cash position of 15.4M.
| Cash & Cash Equivalents | 16.35M |
| Total Debt | 949K |
| Net Cash | 15.4M |
| Retained Earnings | -248.62M |
| Total Assets | 9.58M |
| Working Capital | 8.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10.48M
and capital expenditures -160K, giving a free cash flow of -10.64M.
| Operating Cash Flow | -10.48M |
| Capital Expenditures | -160K |
| Free Cash Flow | -10.64M |
| FCF Per Share | -6.93 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
